DNB Asset Management AS Sells 24,773 Shares of Boston Scientific Corporation $BSX

DNB Asset Management AS trimmed its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 6.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 374,557 shares of the medical equipment provider’s stock after selling 24,773 shares during the period. DNB Asset Management AS’s holdings in Boston Scientific were worth $35,714,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in BSX. Murphy & Mullick Capital Management Corp boosted its stake in shares of Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares during the last quarter. FWL Investment Management LLC acquired a new position in shares of Boston Scientific in the 2nd quarter valued at $26,000. United Community Bank grew its stake in Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 147 shares during the period. Colonial Trust Co SC increased its stake in Boston Scientific by 502.2% during the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 231 shares in the last quarter. Finally, Bangor Savings Bank raised its holdings in Boston Scientific by 94.7% during the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 142 shares during the period. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

BSX stock opened at $52.67 on Friday. Boston Scientific Corporation has a 12 month low of $52.52 and a 12 month high of $109.50. The firm has a market cap of $78.27 billion, a P/E ratio of 22.04, a P/E/G ratio of 0.98 and a beta of 0.62. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The company’s 50-day moving average price is $63.40 and its two-hundred day moving average price is $81.79.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same period in the prior year, the company earned $0.75 earnings per share. The company’s quarterly revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, analysts anticipate that Boston Scientific Corporation will post 3.38 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on BSX. Daiwa Securities Group cut shares of Boston Scientific from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. The Goldman Sachs Group decreased their price target on Boston Scientific from $87.00 to $84.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. Truist Financial lowered their price objective on shares of Boston Scientific from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Thursday, April 23rd. Stifel Nicolaus decreased their target price on Boston Scientific from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Tuesday, April 21st. Finally, Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $93.91.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.